Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

10.15 -0.20 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,975,771
Open 10.38
Bid (Size) 10.15 (10)
Ask (Size) 10.21 (1)
Prev. Close 10.35
Today's Range 10.02 - 10.50
52wk Range 3.210 - 18.33
Shares Outstanding 303,513,872
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize. 
Via The Motley Fool
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+25.31%
+25.31%
1 Month
-12.65%
-12.65%
3 Month
+24.39%
+24.39%
6 Month
-30.14%
-30.14%
1 Year
+108.42%
+108.42%

More News

Read More
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Via The Motley Fool
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
Looking Into Iovance Biotherapeutics's Recent Short Interest
Via Benzinga
Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
What the Options Market Tells Us About Iovance Biotherapeutics
Via Benzinga
3 Monster Biotech Stocks to Buy Before 2025
Via The Motley Fool
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Iovance Biotherapeutics Shares Are Soaring Today
Via The Motley Fool
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
Via InvestorPlace
Topics Earnings
Exposures Financial
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Via Benzinga
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
10 Best Small and Mid-Cap Stocks to Consider Buying in August
Via The Motley Fool
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
Via The Motley Fool
Why Iovance Biotherapeutics Stock Stumbled Today
Via The Motley Fool
Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.